These findings shed light on CHEK1 reduction as a novel mechanism of LR‐disrupting miltefosine and provide a preclinical rationale to broaden the evaluation of LR‐disrupting drugs that preferentially target colorectal CSCs as well as bulk tumour cells. This evidence concerns the gene CHEK1 and neoplasm.